![]() UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. | ![]() Genewiz GENEWIZ specializes in DNA services, including DNA sequencing, gene synthesis, molecular biology, genomic, and regulatory services. | |||
Founding Date | Founding Date 1928 | Founding Date 2003 | Founding Date 1915 | Founding Date 1999 |
Type | Type Public | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more | Locations Dublin, IE HQ Mississauga, CA Vancouver, CA Lyon, FR München, DE Roscommon, IE Villa Guardia, IT see more | Locations København, DK HQ Buenos Aires, AR North Ryde, AU Wien, AT Bruxelles, BE Rio De Janeiro, BR Sofia, BG see more | |
Employees | Employees 9,0521% increase | Employees 2,800 | Employees 5,7072% decrease | Employees 139 |
Valuation ($) | Valuation ($) 34.3 b | Valuation ($) 6.9 b | Valuation ($) 6.2 b | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) €5.6b (FY, 2024) | Revenue (est.) $4.1b (FY, 2024) | Revenue (est.) kr22b (FY, 2024) | Revenue (est.) N/A |
Cost of goods | Cost of goods €1.1b (FY, 2024) | Cost of goods N/A | Cost of goods kr2.5b (FY, 2024) | Cost of goods N/A |
Gross profit | Gross profit €6.2b (FY, 2024) | Gross profit N/A | Gross profit kr19.5b (FY, 2024) | Gross profit N/A |
Net income | Net income €1.1b (FY, 2024) | Net income $560.1m (FY, 2024) | Net income kr3.1b (FY, 2024) | Net income N/A |
Operating ⚠ | ||||
Countries | Countries 35 (FY, 2019) | Countries N/A | Countries 100 (May, 2024) | Countries N/A |
Jazz Pharmaceuticals is an international biopharmaceutical company.
View companyH. Lundbeck is a pharmaceutical company specializing in brain diseases.
View companyGENEWIZ specializes in DNA services, including DNA sequencing, gene synthesis, molecular biology, genomic, and regulatory services.
View company